AELIX Therapeutics is a clinical-stage biotechnology company based in Barcelona, Spain. It is focused on the development of a therapeutic HIV vaccine to be included in cure/eradication strategies. AEL
IX Therapeutics is a spin-off of HIVACAT, the Catalan public-private consortium conducting cutting-edge research in this field. AELIX holds a worldwide, exclusive license for the development and commercialization of the HTI immunogen.
